<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01231061</url>
  </required_header>
  <id_info>
    <org_study_id>SYM008</org_study_id>
    <nct_id>NCT01231061</nct_id>
  </id_info>
  <brief_title>Spinal met_radiosurgery/SBRT Study</brief_title>
  <official_title>Randomized Phase II Study of Image-Guided Radiosurgery / SBRT for Localized Spine Metastasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese University of Hong Kong</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Demonstrate the technical feasibility of treating spine metastases with image-guided&#xD;
      radiosurgery/SBRT&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain control at 3 months post-treatment</measure>
    <time_frame>4 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine the time of onset of pain response of the responders at the treated site(s) using radiosurgery/SBRT</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the duration of pain response at the treated site(s) using radiosurgery/SBRT</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study the adverse events of radiosurgery/SBRT according to the criteria in the CTEP Active Version of the CTCAE</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the radiological response of image-guided radiosurgery/SBRT by RECIST MRI</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2-year Tumor Control Rate</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessment</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Spine Metastasis</condition>
  <arm_group>
    <arm_group_label>Arm A: SBRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: Radiosurgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>SBRT</intervention_name>
    <description>•24 Gy in 3 fractions to cover at least 90% of the defined target volume</description>
    <arm_group_label>Arm A: SBRT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiosurgery</intervention_name>
    <description>16 Gy in 1 fraction to cover at least 90% of the defined target volume</description>
    <arm_group_label>Arm B: Radiosurgery</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. The patient must have localized spine metastasis from the C1 to L5 levels by a&#xD;
             screening imaging study (bone scan, PET, CT, or MRI). A solitary spine metastasis; two&#xD;
             separate spine levels; or up to 3 separate sites are permitted. Each of the separate&#xD;
             sites may have a maximal involvement of 2 contiguous vertebral bodies. A paraspinal&#xD;
             mass ≤ 5 cm is allowed.&#xD;
&#xD;
          2. Zubrod Performance Status 0-2;&#xD;
&#xD;
          3. Age ≥ 18;&#xD;
&#xD;
          4. History/physical examination within 2 weeks prior to registration;&#xD;
&#xD;
          5. No pregnancy for women of childbearing potential;&#xD;
&#xD;
          6. MRI of the involved spine within 4 weeks prior to registration to determine the extent&#xD;
             of the spine involvement. MRI is required as it is superior to a CT scan in&#xD;
             delineating the spinal cord as well as identifying an epidural or paraspinal soft&#xD;
             tissue component. If possible, an MRI with thin slice thickness (&lt;1mm) with 3D&#xD;
             reconstruction quality would be most preferable for treatment planning purpose.&#xD;
&#xD;
          7. Numerical Rating Pain Scale within 1 week prior to registration. The patient must have&#xD;
             a score on the Scale of ≥ 4 for at least one of the planned sites for spine&#xD;
             radiosurgery. Patients taking medication for pain at the time of registration are&#xD;
             eligible.&#xD;
&#xD;
          8. Neurological examination within 1 week prior to registration to rule out rapid&#xD;
             neurologic decline; see Appendix IV for the standardized neurological examination.&#xD;
             Patients with mild to moderate neurological signs are eligible. These neurological&#xD;
             signs include radiculopathy, dermatomal sensory change, and muscle strength of&#xD;
             involved extremity 4/5 (lower extremity for ambulation or upper extremity for raising&#xD;
             arms and/or arm function).&#xD;
&#xD;
          9. Patients with epidural compression are eligible provided that there is no significant&#xD;
             displacement or compression on the spinal cord itself.&#xD;
&#xD;
         10. Patients with a paraspinal mass ≤ 5 cm in the greatest dimension and that is&#xD;
             contiguous with spine metastasis are eligible.&#xD;
&#xD;
         11. Patients must provide study specific informed consent prior to study entry.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Histologies of myeloma or lymphoma.&#xD;
&#xD;
          2. Patients with any spine metastasis with a rating of &lt; 4 on the Numerical Rating Pain&#xD;
             Scale.&#xD;
&#xD;
          3. Non-ambulatory patients.&#xD;
&#xD;
          4. Spine instability due to a compression fracture.&#xD;
&#xD;
          5. &gt; 50% loss of vertebral body height.&#xD;
&#xD;
          6. Significant spinal cord compression or displacement.&#xD;
&#xD;
          7. Patients with rapid neurologic decline.&#xD;
&#xD;
          8. Bony retropulsion causing neurologic abnormality.&#xD;
&#xD;
          9. Prior radiation to the index spine.&#xD;
&#xD;
         10. Patients for whom an MRI of the spine is medically contraindicated.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael KM KAM, FRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Clinical Oncology, Prince of Wales Hospital, The Chinese University of Hong Kong</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Clinical Oncology, Prince of Wales Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <study_first_submitted>October 29, 2010</study_first_submitted>
  <study_first_submitted_qc>October 29, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 1, 2010</study_first_posted>
  <last_update_submitted>July 23, 2014</last_update_submitted>
  <last_update_submitted_qc>July 23, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 24, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese University of Hong Kong</investigator_affiliation>
    <investigator_full_name>CCTU</investigator_full_name>
    <investigator_title>Comprehensive Clinical Trial Unit</investigator_title>
  </responsible_party>
  <keyword>spine metastasis</keyword>
  <keyword>SBRT</keyword>
  <keyword>Radiosurgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

